P3 Health Partners achieved its third consecutive profitable quarter, raising full-year Adjusted EBITDA guidance midpoint to $100 million while highlighting a $200 million value creation pipeline.
P3 Health Partners Inc. reported its third quarter 2026 results, highlighting significant risks regarding its ability to continue as a going concern and the need for additional capital. The company continues to experience net losses and faces challenges maintaining compliance with debt covenants and Nasdaq listing requirements.
P3 Health Partners reported Q3 2026 financial results with revenue of $396 million, up 15% year-over-year, and net income of $30.8 million. The company raised its full-year 2026 Adjusted EBITDA guidance midpoint to $100 million based on strong year-to-date performance and improved network economics.
Term
Q3 2026
“This was another strong quarter for P3. The foundation we have built over the past two years is showing up both in the care our patients receive and in the consistency of our results. We carry real momentum into 2027, as evidenced by our medical cost trend, and I am excited about what lies ahead for our patients, our providers, and our partners.”